Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Buy" from Analysts

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $14.80.

ACHV has been the subject of several analyst reports. Rodman & Renshaw started coverage on shares of Achieve Life Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $12.00 price target for the company. RODMAN&RENSHAW upgraded shares of Achieve Life Sciences to a "strong-buy" rating in a research report on Thursday, November 14th.

Institutional Trading of Achieve Life Sciences

A number of large investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in Achieve Life Sciences during the third quarter worth about $54,000. The Manufacturers Life Insurance Company bought a new position in shares of Achieve Life Sciences during the 2nd quarter valued at about $69,000. MetLife Investment Management LLC grew its position in shares of Achieve Life Sciences by 65.6% in the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 5,939 shares during the period. Verition Fund Management LLC bought a new stake in Achieve Life Sciences during the 3rd quarter worth approximately $113,000. Finally, Renaissance Technologies LLC raised its holdings in Achieve Life Sciences by 134.2% during the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 14,360 shares during the period. Institutional investors own 33.52% of the company's stock.

Achieve Life Sciences Price Performance

Shares of ACHV traded up $0.03 during mid-day trading on Wednesday, hitting $3.27. 261,604 shares of the company traded hands, compared to its average volume of 313,122. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. The business has a 50-day moving average of $3.75 and a 200 day moving average of $4.33. Achieve Life Sciences has a one year low of $2.84 and a one year high of $5.59. The stock has a market capitalization of $112.46 million, a price-to-earnings ratio of -2.89 and a beta of 1.66.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.10). During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, equities analysts expect that Achieve Life Sciences will post -1.17 earnings per share for the current fiscal year.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.